Scandion Oncology A/S (“Scandion Oncology”) announces that its President & CEO, Bo Rode Hansen, has bought additional 10,800 shares in Scandion Oncology resulting in a total holding on 35,900 shares in the Company.
For further information, please contact:
The information was provided by the contact person above for publication, on July 5, 2021 at 16:30 p.m. CEST.
About Scandion Oncology A/S
Scandion Oncology is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate drug, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities, including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the company’s certified advisor on Nasdaq First North Growth Market and can be reached at firstname.lastname@example.org or +46 (0) 40 200 250.